Skip to main content
. 2021 Oct 30;8(6):4852–4862. doi: 10.1002/ehf2.13677

Figure 2.

Figure 2

Risks of cardiovascular mortality, myocardial reinfarction, and hospitalization for HF with sacubitril–valsartan vs. angiotensin‐converting enzyme inhibitors/angiotensin receptor blockers. CI, confidence interval; HF, heart failure; RR, risk ratio.